Search in:

Advanced search

Drug Design, Development and Therapy Volume 10, 2016 - Issue

Submit an article Journal homepage

Open access

137

Views

CrossRef citations to date

Altmetric

Letter

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

Ali T Taher1 Department of Internal Medicine, American University of Beirut, Beirut, LebanonCorrespondence[email protected]

John B Porter2 Department of Haematology, University College London, London, UK

Antonis Kattamis3 First Department of Pediatrics, University of Athens, Athens, Greece

Vip Viprakasit4 Department of Pediatrics and Thalassemia Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand

M Domenica Cappellini5 Department of Internal Medicine, Università di Milano, Ca Granda Foundation IRCCS, Milan, Italy

Pages 4073-4078 | Published online: 15 Dec 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

KontoghiorgheCNKontoghiorghesGJEfficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromesDrug Des Devel Ther201610465481
PubMed Web of Science ®Google Scholar
TaherATPorterJViprakasitVDeferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyBlood2012120597097722589472
PubMed Web of Science ®Google Scholar
TaherATPorterJBViprakasitVDeferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAnn Hematol201392111485149323775581
PubMed Web of Science ®Google Scholar
Novartis Pharmaceuticals [webpage on the Internet]EXJADE^® (deferasirox) US Prescribing Information2015 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdfAccessed August 31, 2016
Google Scholar
NickHWongAAcklinPICL670A: preclinical profileAdv Exp Med Biol200250918520312572995
PubMed Web of Science ®Google Scholar
SteinhauserSHeinzUBartholomaMComplex formation of ICL670 and related ligands with FeIII and FeIIEur J Inorg Chem20042141774192
Web of Science ®Google Scholar
PennellDJPorterJBCappelliniMDEfficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemiaBlood2010115122364237119996412
PubMed Web of Science ®Google Scholar
PennellDJPorterJBPigaAA 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)Blood2014123101447145424385534
PubMed Web of Science ®Google Scholar
WestwoodMAAndersonLJMaceiraAMNormalized left ventricular volumes and function in thalassemia major patients with normal myocardial ironJ Magn Reson Imaging20072561147115117520718
PubMed Web of Science ®Google Scholar
PennellDJCarpenterJ-PRoughtonMCabantchikIZOn improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failureCardiovasc Magn Reson20111345
PubMed Web of Science ®Google Scholar
TaherATPorterJBViprakasitVApproaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxEur J Haematol201492652152624460655
PubMed Web of Science ®Google Scholar
Al-KhaboriMBhandariSAl-HuneiniMAl-FarsiKPanjwaniVDaarSSide effects of deferasirox iron chelation in patients with beta thalassemia major or intermediaOman Med J201328212112423599881
PubMedGoogle Scholar
KarimiMArandiNHaghpanahSEfficacy of deferasirox (Exjade(R)) in modulation of iron overload in patients with beta-thalassemia intermediaHemoglobin201539532732926114738
PubMed Web of Science ®Google Scholar
LadisVBerdousiHGotsisEKattamisADeferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermediaBr J Haematol2010151550450820950401
PubMed Web of Science ®Google Scholar
VoskaridouEPlataEDouskouMTreatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot studyBr J Haematol2010148233233419863539
PubMed Web of Science ®Google Scholar
KarnonJTolleyKOyeeJJewittKOssaDAkehurstRCost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United KingdomCurr Med Res Opin20082461609162118439348
PubMed Web of Science ®Google Scholar

References

DavidoffFDeAngelisCDDrazenJMSponsorship, authorship, and accountabilityJAMA2001286101232123411559271
PubMed Web of Science ®Google Scholar
StuddertDMMelloMMBrennanTAFinancial conflicts of interest in physicians’ relationships with the pharmaceutical industry – self-regulation in the shadow of federal prosecutionN Engl J Med2004351181891190015509824
PubMed Web of Science ®Google Scholar
BraillonABewleySHerxheimerAMarketing versus evidence-based medicineLancet20123809839340
PubMed Web of Science ®Google Scholar
LochouarnMFrance launches new drug regulatory agencyLancet20123799832213622690393
PubMed Web of Science ®Google Scholar
YangZFanDHow to solve the crisis behind Bribegate for Chinese doctorsLancet20123799812e13e1521420729
PubMed Web of Science ®Google Scholar
AndersenMKragstrupJSøndergaardJHow conducting a clinical trial affects physicians’ guideline adherence and drug preferencesJAMA2006295232759276416788131
PubMed Web of Science ®Google Scholar
PsatyBMRennieDClinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industryJAMA2006295232787279016788134
PubMed Web of Science ®Google Scholar
SacristánJABolañosEHernándezJMSotoJGalendeIPublication bias in health economic studiesPharmacoeconomics199711328929210165318
PubMed Web of Science ®Google Scholar
HolmesDSkies darken over drug companiesLancet201237998291863186422616103
PubMed Web of Science ®Google Scholar
BeranDCapewellSde CourtenMThe International Diabetes Federation: losing its credibility by partnering with Nestlé?Lancet20123809844805
PubMed Web of Science ®Google Scholar
KontoghiorgheCNAndreouNConstantinouKKontoghiorghesGJWorld health dilemmas: orphan and rare diseases, orphan drugs and orphan patientsWorld J Methodol20144316318825332915
PubMedGoogle Scholar
KontoghiorgheCNKontoghiorghesGJEfficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromesDrug Des Devel Ther201610465481
PubMed Web of Science ®Google Scholar
KolnagouAKontoghiorgheCNKontoghiorghesGJTransition of thalassaemia and Friedreich ataxia from fatal to chronic diseasesWorld J Methodol20144419721825541601
PubMedGoogle Scholar
KontoghiorgheCNKontoghiorghesGJNew developments and controversies in iron metabolism and iron chelation therapyWorld J Methodol20166111927019793
PubMedGoogle Scholar
U.S. Attorney’s Office [webpage on the Internet]Manhattan U.S. Attorney Announces $60 Million Civil Fraud Settlement with Accredo Health Group over Kickback Scheme Involving Prescription Drug2015 Available from: https://www.fbi.gov/newyork/press-releases/2015/manhattan-u.s.-attorney-announces-60-million-civil-fraud-settlement-with-accredo-health-group-over-kickback-scheme-involving-prescription-drugAccessed August 4, 2016
Google Scholar
LexisNexis Legal Newsroom Litigation [webpage on the Internet]Another Specialty Pharmacy Settles Exjade False Claims Allegations for $45 Million2015 Available from: http://www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2015/05/01/another-specialty-pharmacy-settles-exjade-false-claims-allegations-for-45-million.aspxAccessed August 4, 2016
Google Scholar
REUTERS [webpage on the Internet]U.S. seeks up to $3.35 billion in Novartis kickback lawsuit2015 Available from: http://www.reuters.com/article/2015/06/30/us-novartis-lawsuit-idUSKCN0-PA1ZK20150630Accessed August 4, 2016
Google Scholar
Novartis Pharmaceutical Corporation [webpage on the Internet]Exjade (deferasirox) tablets for oral suspension [prescribing information]East Hanover, NJNovartis Pharmaceutical Corporation2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdfAccessed August 4, 2016
Google Scholar
Novartis Pharmaceuticals [webpage on the Internet]EXJADE® (deferasirox) US Prescribing Information2015 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdfAccessed August 4, 2016
Google Scholar
KontoghiorghesGJTransparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwideHemoglobin200832660861519065341
PubMed Web of Science ®Google Scholar
KontoghiorghesGJA record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?Expert Opin Drug Saf201312560560923688354
PubMed Web of Science ®Google Scholar
CossuPToccafondiCVardeuFIron overload and desferrioxamine chelation therapy in β-thalassemia intermediaEur J Pediatr198113732672717318837
PubMed Web of Science ®Google Scholar
CalvarusoGVitranoADi MaggioRDeferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trialAm J Hematol201590763463825809173
PubMed Web of Science ®Google Scholar
TannerMAGalanelloRDessiCCombined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJ Cardiovasc Magn Reson2008101218298856
PubMed Web of Science ®Google Scholar
WoodJCKangBPThompsonAThe effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron storesBlood2010116453754320421452
PubMed Web of Science ®Google Scholar
TelferPTWarburtonFChristouSImproved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiproneHaematologica200994121777177819815834
PubMed Web of Science ®Google Scholar
Al-KhaboriMBhandariSAl-HuneiniMAl-FarsiKPanjwaniVDaarSSide effects of deferasirox iron chelation in patients with beta thalassemia major or intermediaOman Med J201328212112423599881
PubMedGoogle Scholar
KontoghiorghesGJThe design of orally active iron chelators for the treatment of thalassaemia [PhD thesis]Colchester, UKUniversity of Essex; British Library Microfilm No D66194/8619821243
Google Scholar
KontoghiorghesGMarcusREHuehnsERDesferrioxamine suppositoriesThe Lancet19833228347454
Google Scholar
KontoghiorghesGJAdvances in oral iron chelation in manInt J Hematol199255127381581581
PubMed Web of Science ®Google Scholar
KolnagouAKontoghiorghesGJEffective combination therapy of deferiprone and desferrioxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassaemia: The protocol of the international committee on oral chelatorsHemoglobin200630223924916798649
PubMed Web of Science ®Google Scholar
KontoghiorghesGJNeocleousKKolnagouABenefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamineDrug Saf200326855358412825969
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date